Response Biomedical Corporation Announces Agreement With Jeffrey L. Purvin to Become Chief Executive Officer

Print E-mail
By Marketwired - Medical and overnight viagra Healthcare   
Friday, 13 April 2012 15:54

 

"We are delighted that Jeff has agreed to become our next CEO," said Dr. Peter A. Thompson, Executive Chairman and generic soft tabs cialis Interim CEO. "Jeff's background and cialis tv commercial experience is perfectly suited to help drive Response during this very exciting time for the Company."

Mr. Purvin has over 30 years of experience marketing both consumer and viagra order medical products. From November 2006 to December 2011, he was the Chairman and CEO of Calibra Medical, Inc., where he and the cheap viagra his team developed and viagra online sales gained FDA clearance for a unique insulin delivery device, successfully positioning the company for an exit. Prior to Calibra, as Chairman and CEO of Metrika, Inc., from January 2004 to July 2006, Mr. Purvin and when will viagra go generic his team developed multiple, handheld, disposable, fingerstick-based, point-of-care, in-vitro diagnostic tests which the company sold directly to physicians, consumers and viagra directions 100mg other companies. Before Metrika, from January 2001 to December 2003, Mr. Purvin was a divisional President at Datascope Corporation (a public company, later acquired by Maquet), where he was responsible for marketing interventional cardiology and viagra professional radiology devices to hospitals, worldwide. Mr. Purvin previously served as Vice President, General Manager, in GlaxoSmithKline's $4B Consumer Healthcare division where he marketed scores of well-known, highly advertised consumer packaged goods. Mr. Purvin started his career at Bristol-Myers Squibb, where he marketed pharmaceuticals and what better viagra or cialis consumer products to both physicians and lipitor and viagra consumers.

Mr. Purvin is a member of the Board of Directors at Cardica, Inc. Cardica markets a unique coronary bypass anastomosis connection device to surgeons, worldwide, and is currently developing a unique, multi-firing surgical stapler line. Mr. Purvin is Chair of Cardica's Compensation Committee and 50 mg cialis is a member of its Audit and rx generic viagra Finance Committees. Mr. Purvin earned a B.A. from Brown University and an M.B.A. from The Wharton School, University of Pennsylvania.

Further information on the Company can be found at www.responsebio.com, SEDAR (Canada) www.sedar.com or EDGAR (U.S.) www.sec.gov/edgar/searchedgar/webusers.htm. Information at these sites is typically available within 24 hours of the distribution of the news release.

About Response Biomedical

Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP® platform for clinical and environmental applications. RAMP®represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point of care testing and laboratory use.

The RAMP® system consists of a reader and single-use disposable test cartridges, and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories. RAMP® clinical tests are commercially available for the early detection of heart attack and congestive heart failure through our commercial partners and distributors.

In the non-clinical market, RAMP® Tests are currently provided for the environmental detection of West Nile Virus, and Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin.

Response has achieved CE Marking for its readers and clinical tests and its Quality Management System is registered to ISO 13485: 2003 and ISO 9001: 2008.

Response Biomedical is a publicly traded company listed on the TSX under the trading symbol "RBM" and quoted on the OTC Bulletin Board under the symbol "RPBIF". For further information, please visit the Company's website at www.responsebio.com.

About the RAMP®Reader and RAMP®200 reader

The RAMP® enabling platform is a portable scanning fluorescence quantitative analysis platform for near patient testing that enables rapid and robust quantitative results. The platform includes easy software upgrades, data management capabilities and unique interface options. The RAMP® Reader features a small footprint and attractive ease of use for moderate throughput settings. The RAMP® 200 reader has innovative design features, including the multi-port capability to run 18 tests per hour on one module and up to 36 tests per hour, using three modules. This allows tests to be run on multiple patients simultaneously or multiple assays to be run for one patient. More information on our proprietary RAMP® technology can be found at www.responsebio.com.

Forward-Looking Statements

This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about Response Biomedical Corporation. Examples of forward-looking statements in this press release include statements regarding our expectations for the appointment of a new CEO and the expected start date of that individual.

These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our annual report on Form 10-K, our Annual Information Form and other filings with the Securities and Exchange Commission and Canadian securities regulatory authorities. We do not undertake to update any forward-looking statements.

Read more http://www.marketwire.com/mw/release.do?id=1643814&sourceType=3





BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 
BioMedReports France Becomes 17th Country to Clear Cel-Sci for Phase 3 Cancer Trial; Regeneron and Sanofi Announce Plan For ... http://t.co/uuMu4Ek1To
8hreplyretweetfavorite
BioMedReports Healthcare Review: Tekmira Pharmaceuticals, Orexigen Therapeutics, Amedisys, Sarepta Therapeutics, Cynosure: U... http://t.co/VFWOOzennB
14hreplyretweetfavorite
BioMedReports FDA Issued Form 483 with 10 Inspectional Observations for Impax Taiwan Plant; Pfenex Announces Closing of Init... http://t.co/o9bdAhSIEB
navigation
Benzinga.com supporter Seeking Alpha Certified